1. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants
- Author
-
Rivka Inzelberg, Joab Chapman, Nurith Vardinon, Miriam Y. Neufeld, Mahmoud Abu-Katash, T. A. Treves, Israel Yust, and Amos D. Korczyn
- Subjects
Male ,Aging ,Pathology ,medicine.medical_specialty ,Neurology ,Enzyme-Linked Immunosorbent Assay ,Electroencephalography ,Cognition ,Antiphospholipid syndrome ,Internal medicine ,mental disorders ,Humans ,Medicine ,Dementia ,Stroke ,Aged ,Psychiatric Status Rating Scales ,Autoimmune disease ,medicine.diagnostic_test ,business.industry ,Anticoagulants ,Middle Aged ,Antiphospholipid Syndrome ,medicine.disease ,Erythrocyte sedimentation rate ,Female ,Partial Thromboplastin Time ,Neurology (clinical) ,Tomography, X-Ray Computed ,business ,Biomarkers ,Partial thromboplastin time - Abstract
The increasing prevalence with age of antiphospholipid antibodies (aPL), of dementia and of stroke complicates the study of a causal relationship between antiphospholipid syndrome (APS) and dementia. Prolonged aPTT due to circulating anticoagulants (CAC) may serve as a more specific laboratory marker of APS. In a hospital-based study, we examined all patients with CAC and included 23 who fulfilled standard criteria for primary APS. These patients were assessed for dementia, vascular brain disease, autoimmune disease activity and dementia risk factors. Among CAC-positive APS patients, 13 of the 23 (56%) were demented and these were significantly older (mean age+/-S.E., 68+/-3 years) than the nondemented APS group (n=10, 51+/-4 years; p
- Published
- 2002